Neogen Company NEOG is well-poised to realize within the coming quarters, due to its continued product improvement efforts that improve its current choices and advance its enterprise technique. The Animal Security phase is gaining from sturdy performances of a whole line of consumable merchandise marketed to veterinarians and animal well being product distributors. The mixing of the previous 3M Meals Security enterprise can be very promising. In the meantime, an unfavorable solvency place and macroeconomic impacts stay issues for Neogen’s operations.
The Zacks Rank #3 (Maintain) inventory has declined 51.4% up to now 12 months, underperforming the business’s 3.5% fall in addition to the S&P 500 composite’s 15.7% acquire.
The famend meals and animal security product supplier has a market capitalization of $1.31 billion. The corporate has an estimated earnings development price of 36.4% for fiscal 2026 in contrast with the S&P 500’s 16.7% development. Neogen’s earnings yield of seven.3% favorably compares with the business’s 0.1% yield.
Let’s delve deeper.
Tailwinds for NEOG Inventory
Product Launches: Neogen’s latest key launches embrace the Molecular Detection Assay – Listeria Proper Now, a speedy, enrichment-free resolution for detecting Listeria species within the setting. Neogen launched Igenity BCHF to enhance total bovine coronary heart well being requirements. It additionally launched the Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96), which integrates qualitative pathogen testing options and Quantitative Speedy Enrichment Dehydrated (QRED) media to allow managed development charges for quantitation, permitting poultry producers to confirm the effectiveness of their interventions.
Picture Supply: Zacks Funding Analysis
In December 2024, the corporate launched the Neogen Petrifilm Bacillus cereus Depend Plate, a brand new addition to the Petrifilm product line. Neogen has ongoing improvement initiatives for a number of new and improved diagnostic assessments and different complementary merchandise for each the Meals Security and Animal Security markets, a lot of that are anticipated to be commercially accessible at numerous occasions throughout fiscal 2025 and 2026.
3M Integration Synergy Seems Spectacular: Neogen’s 2022 merger with 3M’s Meals Security enterprise is predicted to generate important long-term worth for shareholders of the mixed firm. The mixed firm could have the improved geographic footprint, modern product choices, digitization capabilities and monetary flexibility to capitalize on sturdy development traits in sustainability, meals security and supply-chain integrity. The transaction additionally added 3M’s globally acknowledged indicator testing model, Petrifilm, which is now a part of Neogen Tradition Media. Neogen has made important progress in integrating the previous 3M Meals Security enterprise, navigating by a fancy course of amid execution and macroeconomic challenges.
With respect to Petrifilm, the corporate not too long ago started preliminary product testing to substantiate that the totally different steps of manufacturing are in a position to execute processes throughout the required parameters. With promising early outcomes, Neogen expects to finish the testing course of throughout the subsequent couple of months, earlier than transitioning particular person SKUs to the road for full validation.
Robust Prospects for Animal Security: Inside the Animal Security phase, Neogen continues to concentrate on driving development within the direct-to-producer beef and dairy segments whereas focusing on actions to right-size the associated fee base to raised align with the present degree of revenues. Within the first quarter of fiscal 2026, the Animal Care product class delivered strong development, led by greater gross sales of biologics and wound care merchandise.
Life Sciences product class development mirrored greater gross sales of substrates and reagents, whereas Biosecurity gross sales had been pushed by development in insect management merchandise. As well as, the genomics enterprise marked the quarter of development since fiscal 12 months 2023, reflecting the strategic exit from sure much less engaging, end-market exposures. The worldwide genomics enterprise had core development of 4%, aided by sturdy efficiency within the bovine market.
What Issues Neogen?
Weak Solvency: Neogen exited the primary quarter of fiscal 2026 with money and money equivalents of $138.9 million and a considerably excessive complete excellent debt of $800.0 million. The debt-to-capital ratio was 27.2%, down 2.9% on a sequential foundation.
International Financial Issues Dent Progress: The present macroeconomic setting has adversely affected Neogen’s monetary operations. Governments and insurance coverage corporations proceed to search for methods to include the rising price of healthcare, probably placing strain on gamers within the healthcare business. Deteriorating worldwide commerce, world inflationary strain, freight costs and rising rates of interest have resulted in greater uncooked materials and labor prices. Moreover, as a result of present steep tariff charges imposed by the U.S. authorities, the corporate expects an roughly $10 million annualized impression, given the standing of surcharges, competitor actions and the timing of sure resourcing alternatives.
NEOG Inventory Estimate Development
Previously 30 days, the Zacks Consensus Estimate for Neogen’s earnings for fiscal 2026 has remained fixed at 45 cents.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $823.8 million, which signifies a 7.9% decline over 2025.
Key Picks
Some better-ranked shares within the broader medical area are BrightSpring Well being Companies BTSG, lllumina ILMN and Omnicell OMCL.
BrightSpring Well being Serviceshas an estimated long-term earnings development price of 53.3% in contrast with the business’s 15.5% development. Its earnings beat the Zacks Consensus Estimate in every of the trailing 4 quarters, with the common shock being 45.1%. BTSG shares have surged 93.9% towards the business’s 0.1% drop up to now 12 months.
BTSG sports activities a Zacks Rank #1 (Robust Purchase) at current. You may see the whole listing of at present’s Zacks #1 Rank shares right here.
Illumina, sporting a Zacks Rank #1, has an earnings yield of three.7% in comparison with the business’s -17.9% yield. Shares of the corporate have dropped 10.8% up to now 12 months towards the business’s 9.9% development. ILMN’s earnings outpaced estimates in three of the trailing 4 quarters and missed on one event, the common shock being 6.7%.
Omnicell, carrying a Zacks Rank #2 (Purchase), has an earnings yield of three.9% towards the business’s -0.9% yield. Shares of the corporate have fallen 7.8% in contrast with the business’s 2.6% drop. OMCL’s earnings surpassed estimates in every of the trailing 4 quarters, with the common shock being 38.7%.
Zacks Naming Prime 10 Shares for 2026
Wish to be tipped off early to our 10 prime picks for the whole lot of 2026? Historical past suggests their efficiency may very well be sensational.
From 2012 (when our Director of Analysis Sheraz Mian assumed duty for the portfolio) by November, 2025, the Zacks Prime 10 Shares gained +2,530.8%, greater than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing by 4,400 corporations to handpick the very best 10 tickers to purchase and maintain in 2026. Don’t miss your probability to get in on these shares once they’re launched on January 5.
Be First to New Prime 10 Shares >>
Omnicell, Inc. (OMCL) : Free Inventory Evaluation Report
Illumina, Inc. (ILMN) : Free Inventory Evaluation Report
Neogen Company (NEOG) : Free Inventory Evaluation Report
BrightSpring Well being Companies, Inc. (BTSG) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
